First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children

BACKGROUND: Heterologous prime boost immunization with chimpanzee adenovirus 63 (ChAd63) and Modified Vaccinia Virus Ankara (MVA) vectored vaccines is a strategy previously shown to provide substantial protective efficacy against P. falciparum infection in United Kingdom adult Phase IIa sporozoite c...

Descripción completa

Detalles Bibliográficos
Autores principales: Tiono, Alfred B., Nébié, Issa, Anagnostou, Nicholas, Coulibaly, Aboubacar S., Bowyer, Georgina, Lam, Erika, Bougouma, Edith C., Ouedraogo, Alphonse, Yaro, Jean Baptist B., Barry, Aïssata, Roberts, Rachel, Rampling, Tommy, Bliss, Carly, Hodgson, Susanne, Lawrie, Alison, Ouedraogo, Amidou, Imoukhuede, Egeruan Babatunde, Ewer, Katie J., Viebig, Nicola K., Diarra, Amidou, Leroy, Odile, Bejon, Philip, Hill, Adrian V. S., Sirima, Sodiomon B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291132/
https://www.ncbi.nlm.nih.gov/pubmed/30540808
http://dx.doi.org/10.1371/journal.pone.0208328

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291132/
https://www.ncbi.nlm.nih.gov/pubmed/30540808
http://dx.doi.org/10.1371/journal.pone.0208328

Ejemplares similares